Royalty Report: Drugs, Vaccine, Cancer – Collection: 239011

License Grant

Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor), royalty-bearing license in the Field, including the right to grant sublicenses, under the Licensor Patent Rights, the Licensor ownership interest in Joint Patent Rights, Licensor Know-How and Licensor Inventions to make, have made, have used, sell, have sold, offer for sale, and import Licensed Products in the Field. Licensee shall not make, use, sell market or promote Licensed Product for use outside the Field. Where the Licensor Patent Rights are themselves licensed from a Third Party, Licensors license shall take the form of a sublicense.

License Property

Licensor Patent Rights shall mean

(a) the patent and patent applications listed, which shall be updated by Licensor as appropriate from time to time, all patent applications heretofore or hereafter filed or having legal force in any country owned by or licensed to Licensor or to which Licensor otherwise acquires rights, which claim a composition, method or process for biologics or technology, including, but not limited to, cells, cell lines, genes, peptides and proteins which are necessary or useful to practice any process or method related to, or to make, use or sell any Licensed Product in the Field, including Inventions, together with any and all patents that have issued or in the future issue therefrom, including utility, model and design patents and certificates of invention, and

(b) all divisionals, continuations, continuations-in-part, continued prosecution applications, requests for continued examination, reissues, renewals, extensions or additions to any such patents and patent applications; all of Section (a) and this Section (b) of this paragraph to the extent and only to the extent that Licensor hereafter will have the right to grant licenses, immunities or other rights thereunder, and any foreign counterparts to those patents and patent applications, and currently consisting of the Licensor Patent Rights described hereto.

(c) Patents and patent applications licensed to Licensor by a Third party or to which Licensor otherwise acquires rights after the effective date of this Agreement shall become part of the Licensor Patent Rights to the extent that Licensor has the right to grant licenses to Licensee in the Field and only to the extent that Licensor is able to do so on economic terms substantially similar to the economic terms of its primary licenses from third parties as of the effective date.

Licensee Patent Rights
1. 'Polypeptides and Polynucleotides From Coagulase-Negative Staphylococci'
U.S. provisional application 60/098,443 filed 8-31-98 and refiled to add additional subject matter as 60/117,119 on 1-25-99. These provisional applications were converted to U.S. application 09/386,962 filed August 31, 1999, and filed as PCT/US99/19728.  (Licensed exclusively to Licensor by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

2. 'Multicomponent Vaccines'
U.S. provisional Application 60/098,439 filed 8-31-98. This was converted to U.S. application 09/386,959 and PCT/US99/19727 on August  31, 1999. (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and Bioresearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14.  No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

3. 'Fibrinogen Binding Proteins From Staphylococcus aureus'
U.S. provisional application filed 11-26-97 as 60/066,815 abandoned in favor of 'Extracellular Matrix-Binding Proteins From Staphylococcus aureus to add additional information, filed 8-31-98 as 60/098,427 converted 11-25-98 to 09/200,650. PCT /US98/25246 was filed 11-25-98.  (Licensed exclusively to Licensee by The Texas A&M University System (TAMUS) and BioResearch Ireland (BRI). TAMUS and BRI reserve the right to use this technology for noncommercial research and educational purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS).

4. 'Fibronectin Binding Protein Compositions and Methods of Use'
U.S. provisional application filed 1-21-97 as 60/036,139, converted 1-21-98 to 09/010,317; PCT filed 1-21-98 as PCT/US98/01222. (Licensed  exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. . The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

5. 'Collagen Binding Protein Compositions and Methods of Use'
U.S. provisional application 60/017,678 filed 5-16-96 converted 5-14-97 to 08/856,253; PCT/US97/08210 filed 5-14-97. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

6. 'S. aureus Fibrinogen Binding Protein Gene'
U.S. application 08/293,728 filed 8-22-94, issued as U.S. patent 6,008,341 on 12-28-99; Div. App. 09/421,868 was filed 10-19-99 and another divisional application was filed 10-5-00. (Licensed exclusively to Licensor by BRI. BRI reserves the right to use this technology for noncommercial research and educational purposes.)

7. 'MHC II Analog From Staphylococcus aureus'
U.S. application filed 5-24-94 as 08/248,021 and issued 7-15-1997 as U.S. patent 5,648,240. (Licensed exclusively from TAMUS through the AM Fund I to Licensor. TAMUS reserves the right to use this technology for noncommercial research and education purposes. The U.S. Government holds certain rights under 37 CFR 410.14. No license is granted under any service mark or trademark of TAMUS. The name of TAMUS may not be used by Licensee except to state that it is a sublicensee of TAMUS.)

8. 'Fibronectin Binding Peptide'
Filings SE 90 2617 filed 8-10-90; U.S. 846,995 filed 6-8-92 now abandoned; U.S. 55,783 filed 5-3-93 now abandoned, U.S. 234,622 filed 4-28-94 issued as U.S. patent 5,440,014 on 8-8-95. (Nonexclusively from Magnus Hook.)

9. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 89 1687 filed 5-11-89; U.S. 520,808 parent filed 5-9-90 issued as U.S. patent 5,175,096 on 12-29-92; U.S. divisional 974,181 filed 11-10-92 now abandoned; U.S. continuation 340,458 filed 11-14-94 issued as U.S. patent 5,652,217, 'Fibronectin Binding Protein' on 7-29-97; U.S. divisional 725,492 filed on 10-4-96 issued as U.S. patent 5,840,846, 'Fibronectin Binding Protein As Well As Its Preparation' on 11-24-98. (Nonexclusively from Magnus Hook.)

10. 'Fibronectin Binding Protein As Well As Its Preparation'
Filings SE 87 2272 filed 6-1-87; U.S. parent 201,028 filed 6-1-88 now abandoned; U.S. continuation 746,087 filed 8-12-91 now abandoned; U.S. continuation 937,817 filed 1-22-93 issued as U.S. patent 5,320,951 on 6-14-94; U.S. divisional 259,000 filed 6-13-94 issued as U.S. patent 5,571,514 'Fibronectin Binding Protein As Well As Its Preparation' on 11-5-96; U.S. divisional 729,767 filed 10-7-96 issued as U.S. patent 5,770,702 'Fibronectin Binding Protein As Well As Its Preparation' on 6-23-98. (Nonexclusively from Magnus Hook.)

11. 'Collagen Binding Protein As Well As Its Preparation'
U.S. application 861,804 filed 8-21-92 now abandoned; U.S. continuation 447,031 filed 5-22-95 issued as U.S. patent 5,851,794 on 12-22 98. (Nonexclusively from Magnus Hook.)

12. 'Method for Prophylactic Treatment of the Colonization of a S. aureus Bacterial Strain By Cell Surface Protein With Fibronectin and Fibrinogen Binding Ability'
Filings SE 8402938 filed 5-30-84; U.S. parent 840,580 filed 1-21-86, now abandoned; U.S. continuation 801,593 filed 12-5-91 and issued as U.S. Patent 5,189,015 on 2-23-93. (Nonexclusively from Magnus Hook.)

13. 'Bacterial Cell surface Protein with Fibronectin, Fibrinogen, Collagen and Laminin Binding Ability, Process for the Manufacture of the Protein and Prophylactic Treatment'
Filings U.S. 06/840,580 filed as PCT/SE85/00227 on 5-30-85; U.S. continuation 07/801,593 filed 12-5-91, now U.S. Patent 5,189,015; U.S. divisional 07/977,151 filed 11-16-92; U.S. continuation 08/118,697 filed 9-10-93 and issued as U.S. Patent 5,980,908 on 11-9-99. (Nonexclusively from Magnus Hook.)

Licensed Product shall mean active human vaccines containing MSCRAMM(TM) proteins derived from S. aureus or S. epidermidis, within the Field the manufacture, use or sale of which, but for the license granted herein, would infringe at least one Valid Claim of Licensor Patent Rights, or utilize Licensor Know-How.

Field of Use

Field shall mean human vaccines for containing MSCRAMM(TM) proteins derived from S. aureus and S. epidermidis for the prevention of S. aureus and S. epidermidis infections, provided, however that the Field shall exclude the use of MSCRAMM(TM) proteins or such vaccines to stimulate antibody titer in plasma donors whose plasma is collected for the purpose of developing and commercializing products containing plasma derived immunoglobulin.

License Grant

The Irish Licensor hereby grants to Licensee an exclusive, worldwide license under Licensed Technology to make, have made, use, and sell the Licensed Products and otherwise exploit the Licensed Patents and Licensed Technology. Such license shall include the right to grant and authorize sublicenses of the same or lesser scope, to the end of the term of this Agreement.

License Property

Licensed Patents shall mean
         1. The S. aureus Fibrinogen Binding Protein Gene, filed 8/22/94 U.S.
         08/293,728.

         2. Fibrinogen Binding Proteins from S. aureus, filed 11/26/97 U.S.
         60/066,815.

         3. Extracellular Matrix Binding Proteins from S. aureus, filed 8/31/98
         U.S. 60/098,427; filed 11/25/98 U.S. 09/200,650 and filed 11/25/98 as
         PCT/US98/25246.

         4. Multicomponent Vaccines, filed 8/31/98 U.S. 60/098,439.

         5. Polypeptides and Polynucleotides from Coagulase-Negative
         Staphylococci, filed 8/31/98 U.S. 60/098,443.

         6. Staphylococcal Adhesions for Donor Select and Donor Stimulation
         Immunization Strategies, filed 8/31/98 U.S. 60/098,449.

Licensed Technology shall mean all inventions, conceptions, reductions to practice, patent filings, technology, methods, compounds, compositions, cell lines, biological materials, proteins, nucleic acids, know-how, information, documents, materials, tests, laboratory notebooks, computer data, and all improvements thereto, including confidential information, related to Staphylococcal surface proteins developed in partnership between Licensor and Trinity College during the period of the Research and Development Agreement executed on February 22, 1996, and extensions thereof;and the 1999 Cooperative Research and Development Agreement executed at the time this Exclusive License Agreement is executed, and extensions thereof.

Field of Use

This agreement pertains to the drug industry relating to the use of certain surface binding proteins from bacteria and gene products thereof for pharmaceutical and diagnostic purposes, which are encompassed by the Licensed Technology and Licensed Patents.

License Grant

Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor), royalty-bearing license in the Field, under the Licensor Patent Rights, the Licensor ownership interest in Joint Patent Rights and Joint Inventions, Licensor Know-How and Licensor Inventions to make, have made, have used, sell, have sold, offer for sale, and import Licensed Products in the Field throughout the world. This grant includes the right for Licensee to grant sublicenses to Licensee Affiliates without consent, either directly or through one or more intermediaries.

License Property

Licensed Product shall mean the component of an in vitro diagnostic device containing Biological Material for use within the Field, the manufacture, use or sale of which, but for the license granted herein, would infringe at least one Valid Claim of Licensor Patent Rights or Joint Patent Rights in any country. For purposes of clarity, component means the consumable portion of the diagnostic device comprising  biologic material (e.g. antibody) and inert material (e.g. plastic vessel) but does not include the hardware (e.g., fluorometer) or sample acquisition device (e.g., nasal swab) used with the component. In addition, Licensed Product includes any Biological Material whose development or manufacture used or uses Licensor Know How.

Licensor Patent Rights shall mean  (a) the claims of the patent and patent applications listed hereto; (b) all patent applications heretofore or hereafter filed or having legal force in any country owned by or licensed to Licensor (and which Licensor has the right to sublicense to Licensee) or to which Licensee otherwise acquires sublicenseable rights, which claim a composition (including but not limited to, Biological Materials), method or process, which are necessary to practice any process or method claimed in the patent and patent applications in the Field or are necessary, to make, have made, have used, sell, have sold, offer for sale, and import any Licensed Product, together with any and all patents that have issued or in the future issue therefrom, including utility, model and design patents and certificates of invention, and (c) patents and patent applications claiming Licensor Inventions; (d) patents and patent applications added; and (e) all divisionals, continuations, continuations-in-part, continued prosecution applications, requests for continued examination, reissues, renewals and extensions of the patents and patent applications and any foreign counterparts to those patents and patent applications, to the extent and only to the extent that Licensor has or hereafter will have the right to grant licenses and sublicenses thereunder.

US 5,886,151 – Candida albicans integrin-like protein
US 6,346,411 – DNA encoding–candida albicans integrin-like protein
US 6,774,219  – Candida albicans gene, integrin-like protein, antibodies, and methods of use

Joint Patent Rights shall mean (a) all claims of patents and patent applications having legal force in any country which claim a Joint Invention, together with any and all patents that issue therefrom, including utility, model and design patents and certificates of invention, and (b) all divisionals, continuations, continuations-in-part, continued prosecution applications, requests for continued examination, reissues, renewals, and extensions or additions to any such patents and patent applications and any foreign counterparts to those patents and patent applications.

Joint Invention shall mean an Invention made or conceived jointly by one or more employees or others acting on behalf of Licensee and by one or more employees or others acting on behalf of Licensor during and in the course of a Development Collaboration Program or in the course of work done under the Prior Agreements. The parties agree that Joint Inventions shall be owned jointly by Licensor and Licensee in accordance with US law, whereby each joint owner shall have the right to use, pledge, practice, license, assign and otherwise transfer and enjoy its rights to and interests in joint inventions without permission of or accounting to the other joint owner(s)), subject to the licenses granted.

Field of Use

Field shall mean in vitro diagnostic devices containing Biological Material for use in detection of Targets in humans and in food.  'Target' shall mean a given species and genus of microorganism detected using Licensed Product. (Staphylococcus aureus and Staphylococcus epidermidis are two distinct Targets.)

License Grant

Licensor hereby grants to Licensee a non-revocable, royalty-bearing exclusive right within the Territory to the Patent Rights in the Field, including the right to sublicense to third parties within the Field, provided that any third party sublicensee shall be subject to all of Licensee's obligations.

License Property

The Parties entered into a joint patent ownership and License Agreement dated as of August 16, 2004, which was later amended and restated as of May 23, 2006, for consideration the sufficiency of which was acknowledged in each Agreement, pursuant to which Licensor granted Licensee a 50% ownership interest in certain patents and patents applications listed in the Joint Ownership Agreement, as well as certain future patent rights, and the parties acknowledge that Licensee would have exclusive rights within a defined filed, while Licensor would have exclusive rights outside that field. Licensee and Licensor now wish to enter a new Agreement superseding the Joint Ownership Agreement so as to specify those future patents and patent applications that are to be subject to joint ownership and so as to restate the Licenses granted in the Joint Ownership Agreement. The Parties acknowledge that the jointly owned and cross-Licensed rights are vital to the parties’ respective plans for development and commercialization and wish to further clarify the parties’ respective rights and provide for continued access to the necessary rights in the event of insolvency.

Jointly Owned Patent Applications shall mean the pending Foreign Patent Applications listed below, including any foreign national patent applications which claim priority to the Foreign Patent Applications and any Future Patent Applications, including any continuations, divisionals, re-exams, reissues and continuations-in-part and any other forms of related applications, that claim domestic or international priority to any of the Issued United States or foreign patents, or pending international or foreign patent applications, specifically listed by patent or application number herein.

(a) Issued US Patents

(i) U.S. 6,268,178 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides; and

(ii) U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.

(iii) U.S. 6,773,899 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(iv) U.S. 6,794,162, entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides;

(b) Foreign Patent Applications

(i) International Patent Applications. All foreign patent applications related to the above-referenced U.S. patents and applications and claiming priority to the following international patent applications under the Patent Cooperation Treaty (PCT)

A. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Licensor-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use

The Licensee plans to develop and commercialize therapeutic methods related to the induction of angiogenesis or wound healing by administration of Fibroblast Growth Factor (FGF); and, the Licensor plans to develop and commercialize recombinant DNA methods for producing peptides/proteins.

Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions. CARDIO-developed devices and methods of use thereof for delivery of angiogenic or wound healing compositions are not included within the Field, and are not subject to joint ownership or any other terms of this Agreement.

License Grant

Licensor hereby grants to Licensee an exclusive license, subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.

Licensor also hereby grants to Licensee an exclusive license to make, use, and/or sell the Licensed Materials in the Territory for the Field of Use. At Licensees request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

License Property

Protein GP96 Vaccination (UMD-107) technology is a platform designed to activate immune responses against cancer or infectious diseases.

U.S. patent application serial number US 61/033,425 entitled 'Heat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 20 March 2008;
PCT patent application number PCT/US2009/001727 entitled 'bleat Shock Protein GP96 Vaccination and Methods of Using Same' and filed on 19 March 2009;
all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT patent application number PCT/US2009/001727 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.

“Patent Rights” shall mean the following United States Patent applications  U.S. patent application serial number US 61/033,425 entitled “ Allogeneic Cancer Cell-Based Immunotherapy” and files on 3 March 2008; PCT patent application number PCT/US2009/001330 entitled “Allogeneic Cancer Cell-based Immunotherapy” and filed on 3 March 2009; all United States patents and foreign patents and patent applications based on these U.S. applications; all divisionals, continuations of the foregoing; and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. patent application serial number US 61/033,425 or PCT application number PCT/US2009/001330 to meet the requirements of 35 U.S.C. 112¶1; and any re-examination or reissues of the foregoing.

Field of Use

Field of Use is for the treatment of cancer relating to all human healthcare and research applications.

License Grant

Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property

The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use

Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

License Grant

University hereby grants to Licensee the exclusive right and license, with the right to sublicense, in the Territory to make, have made, use, sell, and import the Licensed Product in the Field and to practice under the Patent Rights in the Field until the expiration of the last to expire valid claim of the Patent Rights, unless this Agreement is terminated sooner as provided herein.  University reserves the royalty-free, nonexclusive right to practice under the Patent Rights and to use Licensed Product for Non-Commercial Education and Research Purposes.

License Property

Application #06/611,797 – Identification of an IL-13 receptor alpha2 peptide analogue capable of enhancing stimulation of glioma-specific CTL response.

Application #11/231,618 – Peptide Analogs capable of enhancing stimulation of a glioma-specific CTL response.

Patent Rights shall mean University intellectual property described below and assigned to University
(a) The United States and foreign patents and/or patent applications listed;
(b) United States and foreign patents issued from the applications listed and from divisionals, substitutions, continuations and continuation-in-parts of these applications;
(c) United States and foreign patents issued from any of the foregoing, including all reissues, registrations, renewals, reexaminations and extensions thereof; and
(d) Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed.

Field of Use

Field shall mean brain cancer peptide(s) antigen vaccines including systemic use and use in a cell based Peptide antigen vaccine regimen ( excluding cDNA and/or gene therapy based antigen delivery and expression).

Licensee is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.